NeoGenomics
About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Employees: 2,200
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
270% more call options, than puts
Call options by funds: $9.57M | Put options by funds: $2.59M
64% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 36
45% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 67
7% more funds holding
Funds holding: 254 [Q1] → 273 (+19) [Q2]
0.53% more ownership
Funds ownership: 98.24% [Q1] → 98.77% (+0.53%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
22% less capital invested
Capital invested by funds: $1.2B [Q1] → $930M (-$269M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
TD Cowen
Dan Brennan
|
$12
|
Buy
Maintained
|
12 Sep 2025 |
|
Stephens & Co.
Mason Carrico
|
$11
|
Overweight
Maintained
|
2 Sep 2025 |
|
Needham
Mike Matson
|
$14
|
Buy
Maintained
|
29 Aug 2025 |
|
Piper Sandler
David Westenberg
|
$11
|
Overweight
Maintained
|
4 Aug 2025 |
|
Morgan Stanley
Tejas Savant
|
$8
|
Equal-Weight
Maintained
|
30 Jul 2025 |
Financial journalist opinion
Based on 12 articles about NEO published over the past 30 days
